Lipum AB (OSTO:LIPUM) Debt-to-EBITDA : -0.05 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Lipum AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Lipum AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr0.00 Mil. Lipum AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr1.76 Mil. Lipum AB's annualized EBITDA for the quarter that ended in Dec. 2023 was kr-37.61 Mil. Lipum AB's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.05.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Lipum AB's Debt-to-EBITDA or its related term are showing as below:

OSTO:LIPUM' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.11 Med: -0.05 Max: -0.03
Current: -0.11

During the past 5 years, the highest Debt-to-EBITDA Ratio of Lipum AB was -0.03. The lowest was -0.11. And the median was -0.05.

OSTO:LIPUM's Debt-to-EBITDA is ranked worse than
100% of 279 companies
in the Biotechnology industry
Industry Median: 1.36 vs OSTO:LIPUM: -0.11

Lipum AB Debt-to-EBITDA Historical Data

The historical data trend for Lipum AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipum AB Debt-to-EBITDA Chart

Lipum AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

-0.07

-0.03

-0.04

-0.05

Lipum AB Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial										-0.04	-0.03	-0.06	N/A	-0.05

Competitive Comparison of Lipum AB's Debt-to-EBITDA

For the Biotechnology subindustry, Lipum AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lipum AB's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipum AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Lipum AB's Debt-to-EBITDA falls into.

Lipum AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Lipum AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	1.761)	/	-37.007
	=	-0.05

Lipum AB's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	1.761)	/	-37.608
	=	-0.05

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Lipum AB (OSTO:LIPUM) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Lipum AB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Lipum AB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Lipum AB (OSTO:LIPUM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipum AB (OSTO:LIPUM) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

Tvistevagen 48 C, Umea, SWE, 907 36

Website

https://www.lipum.se

Lipum AB is a clinical-stage biopharmaceutical company specializing in the discovery and development of a novel treatment for chronic inflammatory diseases. The candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule (BSSL) of the immune system. The development is supported by solid pre-clinical data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need.

Lipum AB (OSTO:LIPUM) Headlines

No Headlines